Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

Abstract

Aim: Acquired resistance to the targeted agent cetuximab poses a significant challenge in finding effective anti-cancer treatments for head and neck squamous cell carcinoma (HNSCC). To accurately study novel combination treatments, suitable preclinical mouse models for cetuximab resistance are key yet currently limited. This study aimed to optimize an acquired cetuximab-resistant mouse model, with preservation of the innate immunity, ensuring intact antibody-dependent cellular cytotoxicity (ADCC) functionality.

Methods: Cetuximab-sensitive and acquired-resistant HNSCC cell lines, generated in vitro, were subcutaneously engrafted in Rag2 knock-out (KO), BALB/c Nude and CB17 Scid mice with/without Matrigel or Geltrex. Once tumor growth was established, mice were intraperitoneally injected twice a week with cetuximab for a maximum of 3 weeks. In addition, immunohistochemistry was used to evaluate the tumor and its microenvironment.

Results: Despite several adjustments in cell number, cell lines and the addition of Matrigel, Rag2 KO and BALB/C Nude mice proved to be unsuitable for xenografting our HNSCC cell lines. Durable tumor growth of resistant SC263-R cells could be induced in CB17 Scid mice. However, these cells had lost their resistance phenotype in vivo. Immunohistochemistry revealed a high infiltration of macrophages in cetuximab-treated SC263-R tumors. FaDu-S and FaDu-R cells successfully engrafted into CB17 Scid mice and maintained their sensitivity/resistance to cetuximab.

Conclusion: We have established in vivo HNSCC mouse models with intact ADCC functionality for cetuximab resistance and sensitivity using the FaDu-R and FaDu-S cell lines, respectively. These models serve as valuable tools for investigating cetuximab resistance mechanisms and exploring novel drug combination strategies.

Keywords

HNSCC / cetuximab resistance / xenograft mouse model / immunodeficient mice

References

[1] Ferlay J,Soerjomataram I.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int J Cancer2019;144:1941-53

[2] Burtness B,Greil R.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.Lancet2019;394:1915-28

[3] Vermorken JB,Rivera F.Platinum-based chemotherapy plus cetuximab in head and neck cancer.N Engl J Med2008;359:1116-27

[4] Kitamura N,Yoshizawa Y,Kudo Y.Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma.Int J Mol Sci2020;22:240 PMCID:PMC7795499

[5] Ferris RL,Fayette J.Nivolumab for recurrent squamous-cell carcinoma of the head and neck.N Engl J Med2016;375:1856-67 PMCID:PMC5564292

[6] Boeckx C,Wouters A.Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.Cancer Lett2014;354:365-77

[7] Boeckx C,de Beeck KO.Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.Am J Cancer Res2015;5:1921-38 PMCID:PMC4529614

[8] Zaryouh H,Baysal H.The role of akt in acquired cetuximab resistant head and neck squamous cell carcinoma: an in vitro study on a novel combination strategy.Front Oncol2021;11:697967 PMCID:PMC8462273

[9] Baysal H,Zaryouh H.Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.Br J Cancer2020;123:752-61 PMCID:PMC7462851

[10] Eze N,Yang DH.PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.Oral Oncol2019;91:69-78 PMCID:PMC6855599

[11] Lyu J,Tian Z,Ren G.Predictive value of pAKT/PTEN expression in oral squamous cell carcinoma treated with cetuximab-based chemotherapy.Oral Surg Oral Med Oral Pathol Oral Radiol2016;121:67-72

[12] Brisson RJ,Arshad S.A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.Head Neck2019;41:3842-9 PMCID:PMC8258680

[13] Lelièvre SA.Tissue polarity-dependent control of mammary epithelial homeostasis and cancer development: an epigenetic perspective.J Mammary Gland Biol Neoplasia2010;15:49-63 PMCID:PMC2861422

[14] Serebriiskii I,Lamb A,Cukierman E.Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells.Matrix Biol2008;27:573-85 PMCID:PMC2603546

[15] Ghajar CM.Tumor engineering: the other face of tissue engineering.Tissue Eng Part A2010;16:2153-6 PMCID:PMC2947934

[16] HogenEsch H.Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models.J Control Release2012;164:183-6 PMCID:PMC3387503

[17] Zhao H,Shang Z.3D Co-culture of cancer-associated fibroblast with oral cancer organoids.J Dent Res2021;100:201-8

[18] Subtil B,Poel D.Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids.Front Immunol2023;14:1105244 PMCID:PMC9905679

[19] Mattei F,Mencattini A.Oncoimmunology meets organs-on-chip.Front Mol Biosci2021;8:627454 PMCID:PMC8032996

[20] Engelmann L,Koerich Laureano N.Organotypic co-cultures as a novel 3D model for head and neck squamous cell carcinoma.Cancers2020;12:2330 PMCID:PMC7463661

[21] Miserocchi G,De Vita A.Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas.Cancer Biol Med2021;18:502-16 PMCID:PMC8185858

[22] Taylor RJ,Jain A.Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.Cancer Immunol Res2015;3:567-74 PMCID:PMC4681575

[23] Monteverde M,Strola G.The relevance of ADCC for EGFR targeting: a review of the literature and a clinically-applicable method of assessment in patients.Crit Rev Oncol Hematol2015;95:179-90

[24] Baysal H,Zaryouh H.The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies.Front Immunol2021;12:737311 PMCID:PMC8453198

[25] López-Albaitero A.Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.Arch Otolaryngol Head Neck Surg2007;133:1277-81

[26] Roda JM,Butchar JP.The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.Clin Cancer Res2007;13:6419-28

[27] Trivedi S,Concha-Benavente F.Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients.Clin Cancer Res2016;22:5229-37 PMCID:PMC5093040

[28] Voskoboinik I,Trapani JA.Perforin and granzymes: function, dysfunction and human pathology.Nat Rev Immunol2015;15:388-400

[29] Kansy BA,Ding F,Jie HB.Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment.J Immunother Cancer2015;3:73

[30] Pozzi C,Spadoni I.The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.Nat Med2016;22:624-31

[31] Bozec A,Radosevic-Robin N.Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: a preclinical study on an orthotopic xenograft model of head and neck cancer.Head Neck2017;39:151-9

[32] D'Amato V,D’Amato C.The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.Br J Cancer2014;110:2887-95 PMCID:PMC4056056

[33] Iida M,Brand TM.Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab.Mol Cancer Ther2016;15:2175-86 PMCID:PMC5010956

[34] Wang WM,Ma SR.Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.PLoS One2015;10:e0119723 PMCID:PMC4344331

[35] Fridman R,Aranoutova I,Bonfil RD.Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection.Nat Protoc2012;7:1138-44

[36] Niu G,Xie J,Chen X.PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.J Nucl Med2009;50:1116-23 PMCID:PMC6435376

[37] Ward BB,Majoros IJ.Targeted dendrimer chemotherapy in an animal model for head and neck squamous cell carcinoma.J Oral Maxillofac Surg2011;69:2452-9 PMCID:PMC3162993

[38] Chen YF,Lin LH.Establishing of mouse oral carcinoma cell lines derived from transgenic mice and their use as syngeneic tumorigenesis models.BMC Cancer2019;19:281 PMCID:PMC6440159

[39] Shalinsky DR,Lamph WW.A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice.Cancer Res1997;57:162-8.

[40] Stein AP,Smith MA.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.Cancer Med2015;4:699-712 PMCID:PMC4430263

[41] Xia L,Zhiqiang L.Gefitinib enhances radiotherapeutic effects of ¹³¹I-hEGF targeted to EGFR by increasing tumor uptake of hEGF in tumor xenografts.Nucl Med Biol2017;48:63-8

[42] Paidi SK,Dadgar S.Label-free raman spectroscopy reveals signatures of radiation resistance in the tumor microenvironment.Cancer Res2019;79:2054-64 PMCID:PMC6467810

[43] Thomas JM.A lung colony clonogenic cell assay for human malignant melanoma in immune-suppressed mice and its use to determine chemosensitivity, radiosensitivity and the relationship between tumour size and response to therapy.Br J Surg1979;66:696-700

[44] Zhu S,El-Rifai W.DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.Gastroenterology2011;141:1738-48.e2 PMCID:PMC3202055

[45] Pan Y,Chen X.Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer.Thorac Cancer2019;10:686-94 PMCID:PMC6449243

[46] Smith LP.Animal models for the study of squamous cell carcinoma of the upper aerodigestive tract: a historical perspective with review of their utility and limitations. Part A. Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of transplanted xenogeneic human tumors.Int J Cancer2006;118:2111-22

[47] Quesnelle KM,Ratay MK.Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.Cancer Biol Ther2012;13:935-45 PMCID:PMC3414414

[48] Quesnelle KM.Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.Clin Cancer Res2011;17:5935-44 PMCID:PMC3426303

[49] Braig F,Voigtlaender M.Cetuximab resistance in head and neck cancer is mediated by EGFR-K₅₂₁ polymorphism.Cancer Res2017;77:1188-99

[50] Yao Y,Chen L.Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC.Signal Transduct Target Ther2022;7:73 PMCID:PMC8904860

[51] Leonard B,O’Keefe RA.BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC.Cancer Res2018;78:4331-43 PMCID:PMC6072571

[52] Rossa C Jr.Immune-relevant aspects of murine models of head and neck cancer.Oncogene2019;38:3973-88 PMCID:PMC6533118

[53] Ohno S,Sudo K.Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells.Mol Ther2013;21:185-91 PMCID:PMC3538304

[54] Liu Z,Wang Y.A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children.Neuro Oncol2014;16:787-99 PMCID:PMC4022216

[55] Janvier Labs. B6RAG2 immunodeficient mouse: immunodeficient mouse for immunology and oncology research. Available from: https://janvier-labs.com/en/fiche_produit/b6_rag_2_mouse/. [Last accessed on 12 Oct 2023]

[56] Akamatsu Y,Dudley DD.Deletion of the RAG2 C terminus leads to impaired lymphoid development in mice.Proc Natl Acad Sci U S A2003;100:1209-14 PMCID:PMC298752

[57] Shinkai Y,Lam KP.RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.Cell1992;68:855-67

[58] Bleul T,Hildebrand A.Different innate immune responses in BALB/c and C57BL/6 strains following corneal transplantation.J Innate Immun2021;13:49-59 PMCID:PMC7879253

[59] Bertolini TB,Gembre AF.Genetic background affects the expansion of macrophage subsets in the lungs of Mycobacterium tuberculosis-infected hosts.Immunology2016;148:102-13 PMCID:PMC4819146

[60] Foerster F,Heck R.Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells.Oncoimmunology2018;7:e1409929 PMCID:PMC5889278

[61] Fornefett J,Klose K.Comparative analysis of humoral immune responses and pathologies of BALB/c and C57BL/6 wildtype mice experimentally infected with a highly virulent Rodentibacter pneumotropicus (Pasteurella pneumotropica) strain.BMC Microbiol2018;18:45 PMCID:PMC5977748

[62] Jiang X,Yu H,Brunham RC.Differences in innate immune responses correlate with differences in murine susceptibility to Chlamydia muridarum pulmonary infection.Immunology2010;129:556-66 PMCID:PMC2842502

[63] Liu Z,Jia B.Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using ⁹⁰Y-labeled fully human antibody panitumumab.Mol Cancer Ther2010;9:2297-308 PMCID:PMC3629966

[64] Nathan CAO,Rong X.Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.Cancer Res2007;67:2160-8

[65] Herzog AE,Zhang Z.The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells.Cell Death Dis2021;12:988 PMCID:PMC8542035

[66] Formelli F,Supino R.In vivo characterization of a doxorubicin resistant B16 melanoma cell line.Br J Cancer1986;54:223-33 PMCID:PMC2001516

[67] Szadvari I,Babula P.Athymic nude mice as an experimental model for cancer treatment.Physiol Res2016;65:S441-53

[68] Kute TE,Stehle JR Jr.Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.Cancer Immunol Immunother2009;58:1887-96

[69] Rosa R,Zambrano N.In vitro and in vivo models for analysis of resistance to anticancer molecular therapies.Curr Med Chem2014;21:1595-606 PMCID:PMC4082167

[70] Tuccillo C,Troiani T.Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.Clin Cancer Res2005;11:1268-76

[71] Bianco R,Damiano V.Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.Clin Cancer Res2008;14:5069-80

[72] De Pauw I,Van den Bossche J.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.Mol Oncol2018;12:830-54 PMCID:PMC5983215

[73] Studer G,El-Bassiouni M,Glanzmann C.Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT.Acta Oncol2007;46:386-94

[74] Van den Bossche V,Vara-Messler M.Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.Drug Resist Updat2022;60:100806

[75] Simons AL,Mattson DM.Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.Int J Radiat Oncol Biol Phys2007;69:1222-30 PMCID:PMC2267859

[76] Tijink BM,Leemans CR.Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.J Nucl Med2006;47:1127-35

[77] McCall KC,Bartlett R,Carlin S.Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.Int J Radiat Oncol Biol Phys2012;84:e393-9 PMCID:PMC3522091

[78] Blitzer GC,Harris SL.Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck.Int J Radiat Oncol Biol Phys2014;88:761-70 PMCID:PMC3990872

[79] Szturz P,Vermorken JB.How standard is second-line cetuximab in recurrent or metastatic head and neck cancer in 2017?.J Clin Oncol2017;35:2229-31

[80] Gillison ML,Harris J.Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.Lancet2019;393:40-50 PMCID:PMC6541928

[81] Olson B,Lin Y,Patnaik A.Mouse models for cancer immunotherapy research.Cancer Discov2018;8:1358-65 PMCID:PMC8725605

[82] Bozec A,Radosevic-Robin N.Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.Laryngoscope2016;126:E156-63

[83] Bozec A,Fischel JL.The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.Oral Oncol2011;47:340-4

[84] Cassell A,Lee J.Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.Neoplasia2012;14:1005-14 PMCID:PMC3514742

[85] Hoeben BA,Oyen WJ.Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.Int J Cancer2011;129:870-8

[86] Garrido G,Rodriguez HM,Alonso D.7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.Hybrid Hybridomics2004;23:168-75

[87] He X,Joseph S.Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab.Oncotarget2018;9:12250-60 PMCID:PMC5844743